- Home
- MNSB vs ZURA Comparison
MNSB vs ZURA Comparison
Compare MNSB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- ZURA
- Stock Information
- Founded
- MNSB 2003
- ZURA 2022
- Country
- MNSB United States
- ZURA United States
- Employees
- MNSB N/A
- ZURA N/A
- Industry
- MNSB Major Banks
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNSB Finance
- ZURA Health Care
- Exchange
- MNSB Nasdaq
- ZURA Nasdaq
- Market Cap
- MNSB 140.1M
- ZURA 137.2M
- IPO Year
- MNSB N/A
- ZURA N/A
- Fundamental
- Price
- MNSB $19.10
- ZURA $3.74
- Analyst Decision
- MNSB
- ZURA Strong Buy
- Analyst Count
- MNSB 0
- ZURA 9
- Target Price
- MNSB N/A
- ZURA $11.38
- AVG Volume (30 Days)
- MNSB 38.2K
- ZURA 442.4K
- Earning Date
- MNSB 10-27-2025
- ZURA 11-13-2025
- Dividend Yield
- MNSB 2.11%
- ZURA N/A
- EPS Growth
- MNSB N/A
- ZURA N/A
- EPS
- MNSB N/A
- ZURA N/A
- Revenue
- MNSB $69,367,000.00
- ZURA N/A
- Revenue This Year
- MNSB $23.19
- ZURA N/A
- Revenue Next Year
- MNSB $2.92
- ZURA N/A
- P/E Ratio
- MNSB N/A
- ZURA N/A
- Revenue Growth
- MNSB 9.71
- ZURA N/A
- 52 Week Low
- MNSB $15.00
- ZURA $0.97
- 52 Week High
- MNSB $22.98
- ZURA $4.68
- Technical
- Relative Strength Index (RSI)
- MNSB 51.34
- ZURA 50.73
- Support Level
- MNSB $18.15
- ZURA $3.57
- Resistance Level
- MNSB $19.54
- ZURA $4.10
- Average True Range (ATR)
- MNSB 0.46
- ZURA 0.31
- MACD
- MNSB 0.12
- ZURA -0.08
- Stochastic Oscillator
- MNSB 57.36
- ZURA 29.78
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.